Franklin Resources Inc. lowered its position in Aratana Therapeutics Inc (NASDAQ:PETX) by 2.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,940,402 shares of the biopharmaceutical company’s stock after selling 149,158 shares during the period. Franklin Resources Inc. owned approximately 0.14% of Aratana Therapeutics worth $31,247,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PETX. Northern Trust Corp grew its holdings in shares of Aratana Therapeutics by 10.5% in the 2nd quarter. Northern Trust Corp now owns 463,984 shares of the biopharmaceutical company’s stock worth $3,355,000 after acquiring an additional 43,967 shares during the period. Parametric Portfolio Associates LLC grew its holdings in shares of Aratana Therapeutics by 6.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 1,875 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Aratana Therapeutics by 197.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 380,895 shares of the biopharmaceutical company’s stock worth $2,754,000 after acquiring an additional 252,655 shares during the period. Voya Investment Management LLC grew its holdings in shares of Aratana Therapeutics by 22.7% in the 2nd quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 3,610 shares during the period. Finally, State Street Corp grew its holdings in shares of Aratana Therapeutics by 10.2% in the 2nd quarter. State Street Corp now owns 597,180 shares of the biopharmaceutical company’s stock worth $4,317,000 after acquiring an additional 55,480 shares during the period. Institutional investors and hedge funds own 71.07% of the company’s stock.
A number of equities research analysts recently weighed in on PETX shares. HC Wainwright set a $10.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a report on Tuesday, January 16th. CL King started coverage on Aratana Therapeutics in a report on Wednesday, December 27th. They issued a “neutral” rating on the stock. Zacks Investment Research cut Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 17th. Stifel Nicolaus restated a “hold” rating and issued a $6.00 price target on shares of Aratana Therapeutics in a report on Monday, December 18th. Finally, ValuEngine cut Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $8.39.
In other Aratana Therapeutics news, CEO Peter Steven St sold 19,367 shares of the stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $4.77, for a total transaction of $92,380.59. Following the sale, the chief executive officer now owns 672,259 shares in the company, valued at approximately $3,206,675.43. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Craig A. Tooman sold 30,000 shares of the stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $5.27, for a total value of $158,100.00. Following the sale, the insider now owns 75,024 shares in the company, valued at approximately $395,376.48. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Franklin Resources Inc. Lowers Position in Aratana Therapeutics Inc (PETX)” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3285026/franklin-resources-inc-lowers-position-in-aratana-therapeutics-inc-petx.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics Inc (NASDAQ:PETX).
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.